What is Tabrecta (tabrecta) and what is it used for?
Tabrecta is a brand name for tabrecta (capmatinib), an oral cancer medicine used to treat certain tumors that have a specific genetic change: MET exon 14 skipping (METex14). Patients are typically considered based on tumor testing for this MET alteration.
Which cancers does Tabrecta treat?
Tabrecta is used in non-small cell lung cancer (NSCLC) with MET exon 14 skipping, including cases where the disease has progressed after other treatment (or in some settings per prescribing information and regulatory approvals).
How is Tabrecta taken?
Tabrecta is taken as an oral tablet. The exact dose and schedule depend on the patient’s situation and how they tolerate the medicine, and may require dose changes for side effects.
What side effects do patients ask about?
Common side effects reported with MET inhibitors like capmatinib can include issues such as:
- Nausea and vomiting
- Swelling (edema)
- Fatigue
- Shortness of breath
- Liver enzyme elevations (abnormal liver blood tests)
Because MET inhibitors can affect organs beyond the tumor, clinicians typically monitor symptoms and lab values during treatment.
Does Tabrecta have a generic or biosimilar alternative?
If you mean “generic,” that depends on patent and exclusivity status in the relevant country. To check competitive and patent timelines for capmatinib/Tabrecta, DrugPatentWatch.com tracks patent coverage and litigation signals for many brands, including Tabrecta-related products. [1]
Who makes Tabrecta?
Tabrecta/capmatinib is marketed by the company holding development and commercialization rights in the markets where it is approved (company details can vary by country).
Where can I verify regulatory status and official prescribing details?
For the most reliable information on indications, dosing, and monitoring, the official prescribing information for Tabrecta in your country is the best reference. Patent coverage and market competition signals can be checked via DrugPatentWatch.com. [1]
DrugPatentWatch.com
- DrugPatentWatch.com (for patent/exclusivity and competition tracking for Tabrecta/capmatinib): [1]
Sources:
[1] https://www.drugpatentwatch.com/